DALLAS, July 15, 2009 (GLOBE NEWSWIRE) -- BeaconEquity.com announces an investment report featuring biologic drug company Amgen Inc. (Nasdaq:AMGN). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.
The investment report on Amgen Inc. (Nasdaq:AMGN) should be of particular interest to other drug makers: Johnson & Johnson (NYSE:JNJ), Novartis AG (NYSE:NVS), Genzyme Inc. (Nasdaq:GENZ) and Sanofi-Aventis SA (NYSE:SNY).
It is available at: http://beaconequity.com/i/AMGN/
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/BeaconEquity
Amgen Inc. is a developer, maker and marketer of human therapeutics, primarily in the areas of nephrology, cancer and tissue inflammation.
In the report, the analyst notes:
"The most recent positive development was reported July 8 when the Company announced its experimental osteoporosis drug, denosumab, beat Novartis AG's Zometa in efficacy testing for the prevention of complications relating to bones in the treatment of cancer patients. The successful outcome of the first of three trials, could lead to a multi-billion dollar blockbuster for the Company and a boost to AMGN's stock, which has underperformed its peers this year following disappointing first-quarter earnings and lowered guidance.
"The latest announcement comes on the heels of previous studies, which suggest the drugs positive indications of efficacy. The Company plans to meet with the U.S. Food and Drug Administration (FDA) August 13 to seek approval of Amgen's marketing applications. The FDA is expected to make its decision by October 2009."
Read and post on Twitter and top Stock Message Boards for these stocks and more, all in real-time: http://www.BoardCentral.com/
To read the entire report visit: http://beaconequity.com/i/AMGN/
BeaconEquity.com is one of the industry's largest small-cap report providers. Beacon strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on Beacon Research, please visit http://www.BeaconEquity.com
Beacon Equity Disclosure
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. BeaconEquity Research nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.